Appraising the Risk of Harm in HFpEF and the Likelihood of Benefit in HFrEF

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Patient selection committee - Corvia; Axon</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Eli Lilly; Novo Nordisk; Alleviant Medical</li></ul>